Advice

following a full submission assessed under the orphan medicine process:

alectinib (Alecensa®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of alectinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

Download detailed advice125KB (PDF)

Download

Medicine details

Medicine name:
alectinib hydrochloride (Alecensa)
SMC ID:
SMC2012
Indication:
As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
13 August 2018